Katsuya Kato1, Kenichi Gemba2, Kazuto Ashizawa3, Hiroaki Arakawa4, Satoshi Honda5, Naomi Noguchi6, Sumihisa Honda3, Nobukazu Fujimoto7, Takumi Kishimoto8. 1. Department of Diagnostic Radiology 2, Kawasaki Medical School, General Medical Center, 2-1-80 Nakasange, Okayama, 7008505, Japan. 2. Department of Respiratory Medicine, Chugoku-chuo Hospital, 148-13 Oazakamiiwanari, Miyukicho, Fukuyama, 7200001, Japan. 3. Department of Clinical Oncology, Nagasaki University Graduate School of Medicine, 1-7-1 Sakamoto, Nagasaki, 8528102, Japan. 4. Department of Radiology, Dokkyo Medical University, 880, Kita-Kobayashi, Mibu, Tochigi, 3210293, Japan. 5. Department of Radiology, Okayama Rosai Hospital, 1-10-25 Chikkomidorimachi, Okayama, 7028055, Japan. 6. Department of Radiology, Tamano Mitsui Hospital, 3-2-1 Tama, Tamano, 7060012, Japan. 7. Department of Medical Oncology, Okayama Rosai Hospital, 1-10-25 Chikkomidorimachi, Okayama, 7028055, Japan. Electronic address: nobufujimot@gmail.com. 8. Department of Internal Medicine, Okayama Rosai Hospital, 1-10-25 Chikkomidorimachi, Okayama, 7028055, Japan.
Abstract
OBJECTIVES: The primary aim was to reveal the prevalence of lung cancer (LC) and malignant pleural mesothelioma (MPM) in subjects with past asbestos exposure (AE). We also examined pulmonary or pleural changes correlated with the development of LC. MATERIALS AND METHODS: This was a prospective, multicenter, cross-sectional study. There were 2132 subjects enrolled between 2010 and 2012. They included 96.2% men and 3.8% women, with a mean age of 76.1 years; 78.8% former or current smokers; and 21.2% never smokers. We screened subjects using low-dose computed tomography (CT). The CT images were taken with a CT dose Index of 2.7 mGy. The evaluated CT findings included subpleural curvilinear shadow/subpleural dots, ground glass opacity or interlobular reticular opacity, traction bronchiectasia, honeycombing change, parenchymal band, emphysema changes, pleural effusion, diffuse pleural thickening, rounded atelectasis, pleural plaques (PQs), and tumor formation. RESULTS: The PQs were detected in most of subjects (89.4%) and emphysema changes were seen in 46.0%. Fibrotic changes were detected in 565 cases (26.5%). A pathological diagnosis of LC was confirmed in 45 cases (2.1%) and MPM was confirmed in 7 cases (0.3%). The prevalence of LC was 2.5% in patients with a smoking history, which was significantly higher than that in never smokers (0.7%, p = 0.027). The prevalence of LC was 2.8% in subjects with emphysema changes, which was higher than that of subjects without those findings (1.6%); although, the difference was not statistically significant (p = 0.056). The prevalence of LC in subjects with both fibrotic plus emphysema changes was 4.0%, which was significantly higher than that of subjects with neither of those findings (1.8%, p = 0.011). Logistic regression analysis revealed smoking history, fibrotic plus emphysema changes, and pleural effusion as significant explanatory variables. CONCLUSIONS: Smoking history, fibrotic plus emphysema changes, and pleural effusion were correlated with the prevalence of LC.
OBJECTIVES: The primary aim was to reveal the prevalence of lung cancer (LC) and malignant pleural mesothelioma (MPM) in subjects with past asbestos exposure (AE). We also examined pulmonary or pleural changes correlated with the development of LC. MATERIALS AND METHODS: This was a prospective, multicenter, cross-sectional study. There were 2132 subjects enrolled between 2010 and 2012. They included 96.2% men and 3.8% women, with a mean age of 76.1 years; 78.8% former or current smokers; and 21.2% never smokers. We screened subjects using low-dose computed tomography (CT). The CT images were taken with a CT dose Index of 2.7 mGy. The evaluated CT findings included subpleural curvilinear shadow/subpleural dots, ground glass opacity or interlobular reticular opacity, traction bronchiectasia, honeycombing change, parenchymal band, emphysema changes, pleural effusion, diffuse pleural thickening, rounded atelectasis, pleural plaques (PQs), and tumor formation. RESULTS: The PQs were detected in most of subjects (89.4%) and emphysema changes were seen in 46.0%. Fibrotic changes were detected in 565 cases (26.5%). A pathological diagnosis of LC was confirmed in 45 cases (2.1%) and MPM was confirmed in 7 cases (0.3%). The prevalence of LC was 2.5% in patients with a smoking history, which was significantly higher than that in never smokers (0.7%, p = 0.027). The prevalence of LC was 2.8% in subjects with emphysema changes, which was higher than that of subjects without those findings (1.6%); although, the difference was not statistically significant (p = 0.056). The prevalence of LC in subjects with both fibrotic plus emphysema changes was 4.0%, which was significantly higher than that of subjects with neither of those findings (1.8%, p = 0.011). Logistic regression analysis revealed smoking history, fibrotic plus emphysema changes, and pleural effusion as significant explanatory variables. CONCLUSIONS: Smoking history, fibrotic plus emphysema changes, and pleural effusion were correlated with the prevalence of LC.
Authors: Michele Carbone; Harvey I Pass; Guntulu Ak; H Richard Alexander; Paul Baas; Francine Baumann; Andrew M Blakely; Raphael Bueno; Aleksandra Bzura; Giuseppe Cardillo; Jane E Churpek; Irma Dianzani; Assunta De Rienzo; Mitsuru Emi; Salih Emri; Emanuela Felley-Bosco; Dean A Fennell; Raja M Flores; Federica Grosso; Nicholas K Hayward; Mary Hesdorffer; Chuong D Hoang; Peter A Johansson; Hedy L Kindler; Muaiad Kittaneh; Thomas Krausz; Aaron Mansfield; Muzaffer Metintas; Michael Minaai; Luciano Mutti; Maartje Nielsen; Kenneth O'Byrne; Isabelle Opitz; Sandra Pastorino; Francesca Pentimalli; Marc de Perrot; Antonia Pritchard; Robert Taylor Ripley; Bruce Robinson; Valerie Rusch; Emanuela Taioli; Yasutaka Takinishi; Mika Tanji; Anne S Tsao; A Murat Tuncer; Sebastian Walpole; Andrea Wolf; Haining Yang; Yoshie Yoshikawa; Alicia Zolondick; David S Schrump; Raffit Hassan Journal: J Thorac Oncol Date: 2022-04-21 Impact factor: 20.121